These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17428175)

  • 1. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
    Podar K; Richardson PG; Chauhan D; Anderson KC
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
    Yasui H; Hideshima T; Richardson PG; Anderson KC
    Br J Haematol; 2006 Feb; 132(4):385-97. PubMed ID: 16412014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
    Podar K; Shringarpure R; Tai YT; Simoncini M; Sattler M; Ishitsuka K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
    Cancer Res; 2004 Oct; 64(20):7500-6. PubMed ID: 15492276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting multiple myeloma cells and their bone marrow microenvironment.
    Pagnucco G; Cardinale G; Gervasi F
    Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Anderson KC
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines and signal transduction.
    Hideshima T; Podar K; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
    Hideshima T; Anderson KC
    Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The malignant clone and the bone-marrow environment.
    Podar K; Richardson PG; Hideshima T; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):597-612. PubMed ID: 18070708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
    Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
    Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caveolin-1 as a potential new therapeutic target in multiple myeloma.
    Podar K; Anderson KC
    Cancer Lett; 2006 Feb; 233(1):10-5. PubMed ID: 16473666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a new age in the treatment of multiple myeloma.
    Piazza FA; Gurrieri C; Trentin L; Semenzato G
    Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology and treatment of multiple myeloma.
    Tosi P; Gamberi B; Giuliani N
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):81-6. PubMed ID: 16399590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of novel therapeutic targets for multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Anderson KC
    J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.
    Menu E; van Valckenborgh E; van Camp B; Vanderkerken K
    Arch Physiol Biochem; 2009 May; 115(2):49-57. PubMed ID: 19234898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug insight: thalidomide as a treatment for multiple myeloma.
    Kumar S; Anderson KC
    Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of human and viral cytokines in the pathogenesis of multiple myeloma.
    Berenson JR; Sjak-Shie NN; Vescio RA
    Semin Cancer Biol; 2000 Oct; 10(5):383-91. PubMed ID: 11100886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and clinical significance of vascular endothelial growth factor and its receptors in multiple myeloma].
    Liu JR; Luo SK; Li J; Su C
    Ai Zheng; 2007 Jun; 26(6):652-6. PubMed ID: 17562275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signalling and survival pathways in multiple myeloma.
    Bommert K; Bargou RC; Stühmer T
    Eur J Cancer; 2006 Jul; 42(11):1574-80. PubMed ID: 16797970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.
    Koldehoff M; Beelen DW; Elmaagacli AH
    J Leukoc Biol; 2008 Aug; 84(2):561-76. PubMed ID: 18458152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.